公开(公告)号：US20230226099A1

公开(公告)日：2023-07-20

申请号：US17917346

申请日：2021-04-07

Applicant: AALTO UNIVERSITY FOUNDATION SR

Inventor： Christopher JONKERGOUW ,  Nurcin UGUR ,  Markus LINDER ,  Janne RAULA ,  Esko KAUPPINEN ,  Ekaterina OSMEKHINA

IPC: A61K31/724 ,  A61K31/407 ,  A61K31/7036 ,  A61K31/5383 ,  A61K9/00 ,  A61K9/16 ,  A61P31/04

CPC classification number: A61K31/724 ,  A61K31/407 ,  A61K31/7036 ,  A61K31/5383 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/1623 ,  A61P31/04

Abstract: This invention relates to inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient. The present invention relates also to an inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient for use in a method of treating an infection in a subject. In addition, the present invention relates to a method of treating an infection in a subject by administering an inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient to the subject. The inhalable formulation comprising a macrocyclic, cavity-containing compound as a biologically active ingredient is suitable for the treatment of pulmonary or systemic infections caused by Gram-positive or Gram-negative bacteria.